Translation initiation, particularly eIF4A RNA helicase, is emerging as a privileged chemotherapeutic target as numerous studies associate it with the rate of protein biosynthesis, tumor initiation, chemoresistance, cancer stem cell functions and metastasis (Fabbri et al. 2021; Park et al. 2019; Lee et al. 2021; Chan et al. 2019). This evidence concerns the gene EIF4A2 and cancer.